These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33774750)

  • 41. [Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis: therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids].
    Utsugisawa K; Nagane Y; Suzuki S; Suzuki N
    Rinsho Shinkeigaku; 2012; 52(11):1047-50. PubMed ID: 23196511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review.
    Morren J; Li Y
    Muscle Nerve; 2018 Sep; 58(3):344-358. PubMed ID: 29461627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis.
    Tomschik M; Hilger E; Rath J; Mayer EM; Fahrner M; Cetin H; Löscher WN; Zimprich F
    Neurology; 2020 Sep; 95(10):e1426-e1436. PubMed ID: 32641537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The Myasthenia Gravis Activities of Daily Living score and associated factors to distinguish the refractory phase in generalized myasthenia gravis patients with 5 years or more disease duration].
    Sugimoto T; Yamawaki T; Naito H; Ohno N; Giga M; Kono T; Ochi K; Kohriyama T; Nomura E; Maruyama H
    Rinsho Shinkeigaku; 2022 Dec; 62(12):915-921. PubMed ID: 36450489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset.
    Vincent A; Newsom-Davis J
    Clin Exp Immunol; 1982 Aug; 49(2):266-72. PubMed ID: 7127905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased serum acetylcholine receptor α1 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis.
    Uzawa A; Ozawa Y; Yasuda M; Oda F; Kojima Y; Kawaguchi N; Kanai T; Himuro K; Kuwabara S
    J Neuroimmunol; 2020 Feb; 339():577125. PubMed ID: 31855720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early fast-acting treatment strategy against generalized myasthenia gravis.
    Utsugisawa K; Nagane Y; Akaishi T; Suzuki Y; Imai T; Tsuda E; Minami N; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Murai H; Aoki M
    Muscle Nerve; 2017 Jun; 55(6):794-801. PubMed ID: 27603432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors predicting remission in thymectomized patients with acetylcholine receptor antibody-positive myasthenia gravis.
    Kim H; Lim YM; Lee EJ; Oh YJ; Kim KK
    Muscle Nerve; 2018 Dec; 58(6):796-800. PubMed ID: 30020542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
    Greenwood GT; Lynch Z
    Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of myasthenia gravis: a comparison of the natural course and current therapies.
    Seto M; Motomura M; Takeo G; Yoshimura T; Tsujihata M; Nagataki S
    Tohoku J Exp Med; 1993 Jan; 169(1):77-86. PubMed ID: 8211972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?
    Sanders DB; Burns TM; Cutter GR; Massey JM; Juel VC; Hobson-Webb L;
    Muscle Nerve; 2014 Apr; 49(4):483-6. PubMed ID: 23835683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Juvenile myasthenia gravis: a twenty-year experience.
    Castro D; Derisavifard S; Anderson M; Greene M; Iannaccone S
    J Clin Neuromuscul Dis; 2013 Mar; 14(3):95-102. PubMed ID: 23492460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
    Kim YH; Shin HY; Kim SM
    Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
    Nagaishi A; Yukitake M; Kuroda Y
    Intern Med; 2008; 47(8):731-6. PubMed ID: 18421189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study.
    Chou CC; Su IC; Chou IJ; Lin JJ; Lan SY; Wang YS; Kong SS; Chen YJ; Hsieh MY; Hung PC; Wang HS; Chou ML; Lin KL;
    BMC Neurol; 2019 Jul; 19(1):170. PubMed ID: 31319795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
    Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
    J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Minimal manifestation status and prednisone withdrawal in the MGTX trial.
    Lee I; Kuo HC; Aban IB; Cutter GR; McPherson T; Kaminski HJ; Sussman J; Ströbel P; Oger J; Cea G; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BRF; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Verschuuren JJG; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Minisman G; Sonett JR; Wolfe GI;
    Neurology; 2020 Aug; 95(6):e755-e766. PubMed ID: 32611638
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
    Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
    J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reappraisal of Oral Steroid Therapy for Myasthenia Gravis.
    Imai T; Suzuki S; Nagane Y; Uzawa A; Murai H; Utsugisawa K
    Front Neurol; 2020; 11():868. PubMed ID: 32982912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.